Lixte Biotechnology Q2 2025 Earnings Report

Lixte Biotechnology EPS Results

• Actual EPS: -$0.29
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Lixte Biotechnology Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lixte Biotechnology Announcement Details

• Quarter: Q2 2025
• Date: 8/7/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Lixte Biotechnology (NASDAQ:LIXT) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms. These candidates are currently advancing through early-phase clinical trials in solid tumors, where Lixte is evaluating safety, tolerability and preliminary measures of anti-tumor activity. Research and development activities are conducted in collaboration with academic institutions and contract research organizations to leverage cutting-edge science and streamline the path to clinic.

Headquartered in the United States, Lixte Biotechnology maintains its R&D operations in California and works with strategic partners to extend its global reach. The company’s leadership team comprises seasoned executives and scientists with extensive experience in oncology drug development, regulatory affairs and commercial strategy. Through disciplined pipeline management and targeted clinical development, Lixte aims to deliver differentiated therapies that address significant unmet needs in cancer care.